Immunogenicity and Anti-Drug Antibodies: Why the Body Sometimes Fights a Biologic

A biologic is a protein, and the immune system is built to notice proteins that are not the body's own. When it does, it can make anti-drug antibodies, antibodies directed at the medicine itself. Laboratories do not measure this with a single yes-or-no test. They use a tiered strategy: a screening assay flags any antibody that binds the drug, a confirmatory assay proves that binding is specific, a titer assay measures how much is present, and a neutralization assay asks the question that matters most, whether the antibody actually blocks the drug from working. The U.S. Food and Drug Administration lays out this framework in its 2019 final guidance on immunogenicity testing. The central lesson from both that guidance and the immunology literature is that detecting an antibody is not the same as finding a problem.

Why proteins provoke a response

Small-molecule drugs are tiny and chemically simple. Biologic drugs, monoclonal antibodies, engineered enzymes, hormones like insulin, and fusion proteins, are large, folded, and complex. That complexity gives the immune system many features to recognize. Several factors raise or lower the odds of a response: how different the protein is from anything the body already makes, whether the manufacturing process leaves aggregates or impurities, the route and frequency of dosing, and the patient's own immune status. None of these guarantees an antibody will form, and even when one does, the consequences vary enormously. That variability is exactly why the testing has to be structured rather than a single readout.

The tiered assay strategy

The FDA guidance recommends a specific sequence, and each tier answers a narrower question than the one before it.

Screening

The first tier is a screening assay, sometimes called a binding antibody assay. It casts a wide net and is deliberately set to be sensitive, so it will flag samples that may contain antibodies binding the drug. A sensitive screen produces some false positives by design, which is acceptable because later tiers filter them out. The FDA recommends that screening and confirmatory assays reach a sensitivity of at least 100 nanograms per milliliter of antibody, while acknowledging that a higher limit can be justified depending on the product's risk profile.

Confirmatory

A positive screen is not yet a real signal. The confirmatory assay tests whether the binding is genuinely specific to the drug, typically by adding excess drug to the sample and checking whether that competes away the signal. If it does, the antibody is real and drug-specific. If it does not, the screen result was noise. Only samples that clear this tier are called antibody-positive.

Titer

Once a sample is confirmed positive, the titer assay measures the magnitude of the response, usually reported as the dilution at which the signal disappears. A high titer response and a barely-detectable one are both technically positive, but they carry very different weight. Titer also lets clinicians track whether a response is transient, fading over time, or persistent.

Neutralization

The final tier is the neutralizing antibody assay. Binding an antibody to a drug does not automatically stop the drug from working; an antibody can attach to a region that has nothing to do with the drug's active site. A neutralizing antibody, by contrast, blocks the function directly, either by covering the business end of the molecule or by interfering with how it engages its target. Neutralizing antibodies are the subset most likely to reduce efficacy, which is why they get their own dedicated assay.

From a lab finding to a clinical signal

Here is the point that is easiest to lose. A positive result on a screening assay is a starting question, not an answer. As Steven Swanson argues in a 2024 review in Frontiers in Immunology, the great majority of antibodies raised against therapeutic proteins have no measurable effect on the patient. An antibody becomes clinically significant only when it changes something that matters: the drug's pharmacokinetics (how fast it is cleared), its pharmacodynamics (what it does in the body), its efficacy, or its safety.

Demonstrating that link takes more than a positive assay. It requires comparing outcomes in antibody-positive and antibody-negative patients, looking at whether drug levels dropped, whether the response faded, and whether adverse events clustered. The titer and neutralization tiers feed directly into this judgment: a high-titer, persistent, neutralizing response deserves attention, while a low-titer, transient, non-neutralizing one often does not. This is also why cross-study comparisons of immunogenicity rates are treacherous. Reported rates depend heavily on assay sensitivity, drug tolerance (whether circulating drug in the sample masks the antibody), sampling timing, and the cut points a lab chose. A product that looks more immunogenic on paper may simply have been tested with a more sensitive assay.

A few consequences are worth naming plainly. Anti-drug antibodies can accelerate clearance and quietly erode efficacy over months. In rarer cases they can cause hypersensitivity reactions. The most serious scenario, uncommon but important, is when antibodies against a biologic cross-react with the patient's own equivalent protein. The tiered system exists precisely so that these serious situations can be distinguished from the far more common harmless ones.

For anyone reading a study or a lab report, the practical takeaway is to ask which tier a result came from. "Antibody detected" from a screen alone means little. Confirmed, titered, and characterized for neutralization is where the finding starts to carry clinical meaning.

This article is educational and is not medical advice; decisions about any specific biologic belong with a qualified clinician who knows the individual case.